Balinatunfib
Based on 1 Customer Validation
Balinatunfib (SAR-441566) is an orally active inhibitor of TNFR1 signaling. By binding to the central pocket of the soluble TNFα (sTNFα) trimer, Balinatunfib stabilizes an asymmetric conformation, blocking its binding to TNFR1 (without affecting TNFR2) and thus inhibiting downstream pathways. Balinatunfib has anti-inflammatory activity, and can be used in the study of autoimmune diseases.
For research use only. We do not sell to patients.
- Purity: 99.94%
- CAS No.: 2248726-53-4
- Formula: C27H24F2N6O2
- Molecular Weight:502.52
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Balinatunfib (1-1000 nM; 4 h) efficiently inhibits the expression of CD11b on granulocytes activated by Zymosan (HY-159069) in human whole blood, with an IC50 of 35 nM and an IC90 of 163 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pharmacokinetic Analysis in Male Animals[2]
| Species | Route | Dose (mg/kg) | tmax (h) | Cmax (ng/mL) | AUCinf (ng.h/mL) | CL (L/h/kg) | Vz (L/kg) | T1/2,z (h) | Bioavailability (%) |
| Rat | i.v. | 1 | / | 424 | 731 | 1.38 | 4.1 | 2.1 | / |
| Rat | p.o. | 3 | 4 | 73.6 | 573 | / | / | / | 26 |
| Dog | i.v. | 1 | / | 1510 | 4200 | 0.267 | 2.68 | 7.00 | / |
| Dog | p.o. | 30 | 2 | 6920 | 131000 | / | / | / | 108 |
| Dog | p.o. | 100 | 7 | 6320 | 258000 | / | / | / | 62 |
| Cynomolgus monkey | i.v. | 1 | / | 774 | 2970 | 0.355 | 2.59 | 6.66 | / |
| Cynomolgus monkey | p.o. | 3 | 2 | 609 | 6620 | / | / | / | 67 |
| Cynomolgus monkey | p.o. | 10 | 6 | 1250 | 20000 | / | / | / | 68 |
| Cynomolgus monkey | p.o. | 20 | 8 | 2490 | 45200 | / | / | / | 77 |
| Cynomolgus monkey | p.o. | 100 | 6 | 3640 | 107000 | / | / | / | 36 |